On August 6th, 2026, Avalo Therapeutics, Inc. (Nasdaq: AVTX), headquartered in Wayne, PA, revealed their business developments and financial outcomes for the second quarter of the year. This clinical stage biotech firm focuses on creating treatments that aim at the IL-1β pathway to combat immune-mediated inflammatory illnesses.